Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study

The multinational phase 3 CheckMate 238 trial compared adjuvant therapy with nivolumab versus ipilimumab among patients with resected stage III or IV melanoma (N = 906). In this Japanese subgroup analysis of CheckMate 238 (n = 28; nivolumab, n = 18; ipilimumab, n = 10), both the 12‐ and 18‐month rec...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Dermatol
Auteurs principaux: Yokota, Kenji, Uchi, Hiroshi, Uhara, Hisashi, Yoshikawa, Shusuke, Takenouchi, Tatsuya, Inozume, Takashi, Ozawa, Kentaro, Ihn, Hironobu, Fujisawa, Yasuhiro, Qureshi, Anila, de Pril, Veerle, Otsuka, Yasushi, Weber, Jeffrey, Yamazaki, Naoya
Format: Artigo
Langue:Inglês
Publié: John Wiley and Sons Inc. 2019
Sujets:
Concise Communications
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6916343/
https://ncbi.nlm.nih.gov/pubmed/31638282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1346-8138.15103
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires